Jpmorgan Chase & CO Moleculin Biotech, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.14 Trillion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024
BUY
$0.41 - $0.86 $6 - $13
16 Added 44.44%
52 $0
Q3 2023

Nov 14, 2023
BUY
$0.38 - $0.72 $13 - $25
36 New
36 $0
Q2 2022

Aug 11, 2022
SELL
$1.19 - $2.0 $706 - $1,188
-594 Closed
0 $0
Q1 2022

May 11, 2022
BUY
$1.23 - $1.9 $730 - $1,128
594 New
594 $1,000

Others Institutions Holding MBRX

# of Institutions
2
Shares Held
3.35K
Call Options Held
0
Put Options Held
0
View Full List

About Moleculin Biotech, Inc.

MBRX Quotes by TradingView
  • Ticker MBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,606,700
  • Market Cap $72.7M
  • Description
  • Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....
More about MBRX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email